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Abstract
Background: Intensity-modulated radiation therapy (IMRT) provides excellent locoregional control for
nasopharyngeal carcinoma (NPC), and has gradually replaced two-dimensional conventional radiotherapy as the
first-line radiotherapy technique. Furthermore, in the new seventh edition of the American Joint Committee on
Cancer (AJCC) staging system, retropharyngeal lymph nodes were upgraded from N0 to N1 disease as a result of
their negative impact on the distant metastasis-free survival (DMFS) rates of NPC. This retrospective study was
conducted in order to review the treatment outcomes and patterns of failure in NPC patients with N0 disease after
IMRT in order to effectively guide treatment in the future.
Methods: We retrospectively reviewed data from 506 biopsy-proven nonmetastatic NPC patients. There were 191
patients with negative cervical lymph node involvement. According to the seventh edition of the American Joint
Committee on Cancer (AJCC) staging system, 110 patients (21.7%) were staged with N0 disease, and 81 patients
(16.0%) were reclassified with N1 disease due to the presence of RLN metastasis. All patients received IMRT as the
primary treatment.
Results: In patients with negative cervical lymph node involvement, distant metastasis-free survival (DMFS) was
significantly higher in patients without retropharyngeal lymph node (RLN) metastasis than those with RLN
metastasis (95.9% vs. 88.1% respectively, P = 0.04). For N0 disease, the 5-year overall survival (OS), local relapse-free
survival (LRFS), nodal relapse-free survival (NRFS) and DMFS rates were 93.8%, 97.1%, 99.1% and 95.9%, respectively.
For T1N0, T2N0, T3N0 and T4N0, OS was 97.8%, 100%, 93.8% and 76.9%, LRFS was 100%, 92.9%, 100% and 88.9%
and DMFS was 96.6%, 90.9%, 100% and 93.3%, respectively. OS and LRFS were higher in T1-3 N0 patients than
T4N0 patients (P < 0.01 and P = 0.01, respectively).
Conclusions: The seventh edition of the AJCC N-staging system improves prognostic accuracy by upgrading RLN
metastasis to N1 disease. IMRT produces excellent survival rates in T1-3 N0 disease; however, T4N0 disease remains
a challenge and additional improvements are required to achieve a favorable prognosis for these NPC patients.
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Although nasopharyngeal carcinoma (NPC) is rare in
most of the world, it is endemic in certain regions, espe-
cially Southeast Asia. The incidence of NPC in Southern
China is approximately 30 to 80 per 100,000 people per
year [1]. Newly diagnosed NPC without distant metasta-
sis is typically treated with radiotherapy, rather than by
surgical intervention [2].
The tumor-node-metastasis (TNM) staging system for
NPC is used to evaluate prognosis, aid treatment plan-
ning and facilitate the stratification of treatment. In gen-
eral, the T-classification is prognostic of local control,
whereas the N-classification can significantly predict
neck and distant control [3]. In N0 disease, the T-classi-
fication is the major factor which affects prognosis.
When N0 patients are treated with two-dimensional
conventional radiotherapy, the 5-year overall survival
(OS) rate is 73%-87%, and the local relapse-free survival
(LRFS) rate is 88.6% [4-6]. Concurrent chemotherapy/
radiotherapy plus adjuvant chemotherapy is recom-
mended for T2-4 N0 disease by the National Compre-
hensive Cancer Network (NCCN) clinical practice
guidelines.
Recently, intensity-modulated radiotherapy (IMRT)
has gradually replaced two-dimensional conventional
radiotherapy as the primary radiotherapy technique.
Compared to two-dimensional conventional radiother-
apy, IMRT improves tumor target conformity and allows
safer dose escalations [7]. Lee et al. reported that the 4-
year local progression-free survival rate after IMRT was
97% [8], and subsequent studies have achieved similar
results [9,10]. As the locoregional control rate achieved
using IMRT is greater than 90%, the prognostic power
of the T-classifications has decreased [11], and excellent
results can potentially be obtained using IMRT in N0
disease.
The TNM system of the seventh edition of the Ameri-
can Joint Committee on Cancer (AJCC) staging system
for NPC considers metastasis of the retropharyngeal
lymph nodes (RLN). The classification of negative cervi-
cal lymph nodes with RLN metastasis as N0 disease in
the sixth edition of the AJCC staging system has been
upgraded to N1 disease in the seventh edition [12].
Tang et al. [13] and Tham et al. [14] reported that
patients with RLN metastasis and negative cervical
lymph nodes have a similar risk of distant metastasis to
N1 disease, and proposed that patients with RLN metas-
tasis should be classified with N1 disease, regardless of
laterality. Therefore, patients classified with N0 disease
according to the seventh edition of the AJCC staging
system, where RLN metastasis has been upgraded to N1
disease, may have a better prognosis than patients
staged with N0 disease according to the previous
editions.
Only few studies have reported the treatment out-
comes after IMRT in NPC patients with N0 disease
according to the seventh edition of the AJCC staging
system, and additional data on the recurrence patterns
and survival rates is required to generate new treatment
strategies. This study was conducted in order to deter-
mine the treatment outcomes and the patterns of failure
in NPC patients with N0 disease after IMRT, in order
to more effectively guide future treatment.
Methods
Patient characteristics
This retrospective study was approved by the Institu-
tional Review Board of Sun Yat-Sen University, Guangz-
hou, China. All NPC patients treated with IMRT at the
Sun Yat-Sen University Cancer Center between January
2003 and December 2006 were eligible, and 506 patients
with newly diagnosed, nonmetastatic, histologically pro-
ven NPC disease were enrolled in the study.
All patients completed a pre-treatment evaluation
which included a complete patient history, physical
examination, hematology and biochemistry profiles, MRI
scan of the neck and nasopharynx, chest radiography,
abdominal sonography and a whole body bone scan
using single photon emission computed tomography. In
addition, 130 (25.4%) patients also underwent a positron
emission tomography-computed tomography (PET-CT)
scan. All patients were restaged according to the seventh
edition of the AJCC system [12]. The distribution of T
classification, N classification, and overall stage was as
follows: T1: 162 patients (32.0%); T2: 77 patients
(15.2%); T3: 127 patients (25.1%); T4: 140 patients
(27.7%);
N0:110 patients (21.7%); N1: 252 patients (49.8%); N2:
97 patients (19.2%); N3: 47 patients (9.3%); stage I: 60
patients (11.9%); stage II: 118 patients (23.3%); stage III:
150 patients (29.6%); and stage IV: 178 patients (35.2%).
A total of 81 patients that were negative for spread to
cervical lymph nodes (16.0%) were reclassified with N1
disease due to the presence of RLN metastasis.
Of the 110 patients with N0 disease, the median age
of the cohort was 43 years (range: 13-75 years), and
included 92 males and 18 females (male/female ratio,
5.1:1). Histologically, 0.9% of cases were classified as
World Health Organization (WHO) grade I disease and
99.1% were WHO grade II/III disease (Table 1).
Imaging protocol
All patients underwent MRI scans using a 1.5-T system
(Signa CV/i; General Electric Healthcare, Chalfont St.
Giles, United Kingdom) and the region from the supra-
sellar cistern to the inferior margin at the sternal end of
the clavicle was examined with a head-and-neck com-
bined coil. T1-weighted fast spin-echo images in the
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spin-echo MR images in the axial plane (repetition time,
4000-6000 ms; echo time, 95-110 ms) were obtained
before injecting the contrast material. After intravenous
administration of gadopentetate dimeglumine (Gd-
DTPA; Magnevist, Schering, Berlin, Germany) at a dose
of 0.1 mmol/kg, spin-echo T1-weighted axial and sagit-
tal sequences and spin-echo T1-weighted fat-suppressed
coronal sequences were performed sequentially, with the
same parameters used prior to Gd-DTPA injection,
using a section thickness of 5 mm and a matrix size of
512 × 512. All MR images were reviewed by two radiol-
ogists with more than 10 years of experience in the MR
imaging of head and neck cancers. All images were eval-
uated independently, and disagreements were resolved
by consensus.
Treatment
All patients were treated by IMRT using the PEA-
COCK-MIMiC system (Corvus
® 3.0; Nomos Corpora-
tion, Alderley Qld, Australia) and VARIAN 6MV-
photons [15]. In brief, patients were immobilized in a
supine position using a thermoplastic mask. After
administration of intravenous contrast material, 3 mm
CT slices depicting the head area were acquired until 2
cm below the sternoclavicular joint. The primary tumor
area and the upper-neck area above the caudal edge of
the cricoid cartilage were treated by IMRT. Target
volumes were delineated according to our institutional
treatment protocol, in agreement with the International
Commission on Radiation Units and Measurements
Reports 50 and 62. The clinical target volumes (CTV)
were individually delineated on the basis of the tumor
invasion pattern. The prescribed radiation dose was
applied as follows: a total dose of 68 Gy in 30 fractions
at 2.27 Gy/fraction to the planning target volume (PTV)
of the gross tumor volume of the primary tumor (GTV-
P), 60-64 Gy to the PTV of the nodal gross tumor
volume (GTV-N), 60 Gy to the PTV of CTV-1 (i.e., the
high-risk regions), and 54 Gy to the PTV of CTV-2 (i.e.,
the low-risk regions) and CTV-N (i.e., the neck nodal
regions). A total of 43.6% (48/110) of the N0 disease
patients only received prophylactic irradiation to the
upper neck lymph drainage region, including Levels II,
III and VA of the upper neck lymph nodes, excluding
the Level IV and VB and supraclavicular lower neck
lymph node drainage areas. For the remainder of the N0
and all N1-3 disease patients, an anterior cervical field
was used for irradiation of the lower neck. All patients
were treated with one fraction daily for 5 days per week.
Chemotherapy was administered to 88.6% (295/333) of
the patients with Stage III or IV disease and 82.3% (28/
34) of the patients with T3-4 N0 disease. Chemotherapy
included concurrent chemotherapy alone, concurrent
chemotherapy combined with induction chemotherapy
and/or adjuvant chemotherapy in conjunction with a
platinum-based therapeutic clinical trial. Details of the
chemotherapy agents and dose intensity used are pro-
vided in Table 2. When possible, salvage treatments,
including afterloading, surgery and chemotherapy were
provided in the event of documented relapse or persis-
tent disease.
Follow-up
After the completion of radiotherapy, all patients were
followed up every 1-3 months during the first 2 years,
every 6 months in years 2 to 5 and annually thereafter.
Each follow up included a physical examination, flexible
endoscopy, basic serum chemistry, chest x-ray, liver and
abdomen ultrasound and bone scan. MRI of the head
and neck was performed approximately 3 months after
Table 1 Clinicopathological features in the study
population of 110 nasopharyngeal carcinoma patients
with N0 disease, according to the seventh edition of the
American Joint Committee on Cancer (AJCC) staging
system
Characteristics Number of patients (%)
Age (years)
< 50 76 (69.1%)
≥50 34(30.9%)
Gender
Male 92 (83.6%)
Female 18 (16.4%)
Pathological features
WHO grade I 1 (0.9%)
WHO grade II/III 109 (99.1%)
T-category
T1 60 (54.5%)
T2 16 (14.5%)
T3 16 (14.5%)
T4 18(16.4%)
Table 2 Details of the chemotherapy schedule and doses
used for stage T3-4 N0 nasopharyngeal carcinoma
patients.
Mode of treatment Number of patients %
RT alone 6 17.6
CCRT 7 20.5
NAC + RT 2 5.9
NAC + CCRT 16 47.1
NAC + CCRT + ADC 3 8.8
CCRT, concomitant chemo-radiotherapy (cisplatin, 80 mg/m
2 on day 1, 22 and
43 or 40 mg/m
2 weekly); NAC, neoadjuvant chemotherapy (cisplatin, 80 mg/
m
2 day 1; 5-flourouracil, 800 mg/m
2 days 1-5); RT, radiotherapy; ADC, adjuvant
chemotherapy (cisplatin, 80 mg/m
2 day 1; 5-flourouracil, 800 mg/m
2 days 1-5).
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after. The median follow-up period was 56.8 months
(range: 3.1-102 months).
Statistical methods
The following end points were assessed: overall survival
(OS), disease-specific survival (DSS), local relapse-free
survival (LRFS), nodal relapse-free survival (NRFS) and
distant metastasis-free survival (DMFS). Time was mea-
s u r e df r o mt h es t a r to ft r e a t ment (radiotherapy and/or
chemotherapy) to the time of the first failure or last
examination. OS was measured from the date of first
radiotherapy or chemotherapy to death due to any
cause. Patient who were alive were censored. DSS was
defined as time to death as a result of NPC, or as a
result of toxicity from radiotherapy or chemotherapy. As
for DSS, deaths that were unrelated to NPC or treat-
ment were censored. Similar definitions were used for
LRFS and DMFS analyses. SPSS 11.0 software was used
for the statistical analysis. The actuarial rates were cal-
culated using the Kaplan-Meier method [16], and the
differences were compared using the log-rank test. Mul-
tivariate analyses with the Cox proportional hazards
model were used to test the independent significance of
the predictors [17], and two-tailed P values less than
0.05 were considered statistically significant.
Results
Treatment outcomes
The 5-year survival rates were as follows: OS, 83.4%;
LRFS, 93.7%; NRFS, 97.2%; and DMFS, 84.8%. A total of
38 patients (7.5%) developed locoregional recurrence, 74
patients (14.6%) developed distant metastases, and 81
patients (16.0%) died. In addition, 11 patients (2.2%)
developed both locoregional recurrences and distant
metastases, 18 patients (3.6%) had isolated local recur-
rences, 7 patients (1.4%) had isolated regional recur-
rences and 63 patients (12.5%) had isolated distant
metastases.
The 191 patients with negative cervical lymph node
involvement were divided 2 groups. Group 1 included
the 110 patients without RLN metastasis, and Group 2
included the 81 patients with RLN metastasis. DMFS
was significantly higher in Group 1 than Group 2 (5-
year DMFS: 95.9% vs. 88.1%, P = 0.04). No significant
difference was observed in the NRFS and OS of Group
1 and Group 2 (5-year NRFS: 99.1% vs. 97.4%, P = 0.38;
5-year OS: 93.8% vs. 88.0%, P = 0.14; Figure 1).
In this study, 110 patients (21.7%) were staged with
N0 disease according to the seven edition of the AJCC
staging system. In patients with N0 disease, the 5-year
OS, LRFS, NRFS and DMFS rates were 93.8%, 97.1%,
99.1% and 95.9%, respectively (Figure 2). Of the N0
patients, five developed recurrence or metastasis; one of
these developed local recurrence and distant metastases,
one developed local and regional recurrence and then
distant metastases, one developed isolated local recur-
rences and two developed isolated distant metastases.
Local recurrence in N0 disease
Of the 110 N0 patients, three developed local recur-
rence; one of these patients had T2N0 disease and two
patients had T4N0 disease. Age (≤50 years vs. > 50
years), gender, nasal cavity extension, oropharyngeal
extension, parapharyngeal space extension, skull base
erosion, paranasal sinus extension, hypopharyngeal
extension, orbit extension, masticator space extension,
cranial nerve palsy and intracranial extension were ana-
lyzed as prognostic factors in N0 disease. Univariate
analysis revealed that paranasal sinus extension, orbit
Figure 1 Distant metastasis-free survival, nodal relapse-free survival and overall survival of nasopharyngeal carcinoma patients with
negative cervical lymph node involvement stratified according to the absence of retropharyngeal lymph node (RLN) metastasis
(Group 1) and presence of RLN metastasis (Group 2).
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prognostic factors for LRFS (all P < 0.01). Multivariate
analysis was performed to test the significance of the
independent variables, including all of the prognostic
factors in the Cox proportional hazards model, and
intracranial extension was shown to be a significant
independent predictor of LRFS (HR: 29.5, CI: 2.6-334.4,
P < 0.01).
Distant metastasis and regional recurrence of N0 disease
Four of the 110 N0 patients developed distant metasta-
sis; two of these patients had T1N0 disease, one had
T2N0 disease and one had T4N0 disease. All of the
prognostic factors were tested using univariate analysis
and none were found to significantly determine DMFS.
Only one patient with T4N0 disease developed Level
II lymph node recurrence, and this patient received pro-
phylactic irradiation of the retropharyngeal area and the
Level II, III, IV and V lymph node regions. At the time
of lymph node recurrence, the patient was also found to
have developed a local recurrence, and this patient
developed distant metastases after 14 months.
Survival of N0 disease according to AJCC T-classification
In T1N0, T2N0, T3N0 and T4N0 disease, the OS rates
were 97.8%, 100%, 93.8% and 76.9%, respectively; and
t h eD S Sr a t e sw e r es a m ea st h eO Sr a t e s .T h eL R F S
rates were 100%, 92.9%, 100% and 88.9% and the DMFS
rates were 96.6%, 90.9%, 100% and 93.3%, respectively.
The OS and DSS rates were higher in T1-3 N0 patients
than T4N0 patients (P < 0.01 for both). Local failure
rates were significantly higher in the T4N0 subset (P =
0.01), but there were no significant difference in DMFS
between T1-3 N0 and T4N0 patients (P = 0.60, Figure
3). Of the 110 N0 patients, three had local failure; one
of these had T2N0 disease and the other two had T4N0
with intracranial extension (Table 3).
Discussion
The 5-year relative survival rate for all NPC patients has
increased from approximately 50% to 75% over the past
ten years [15,18]. Advances in technology and the
increasing availability of both diagnostic and therapeutic
facilities have made significant contributions to this
achievement. However, the introduction of new thera-
peutic interventions or technologies requires a reevalua-
tion of the treatment outcomes and the patterns of
failure in NPC patients with N0 disease after IMRT, in
order to effectively guide treatment in the future.
RLN metastasis classification
According to the sixth edition of the AJCC staging sys-
tem, Tang et al. [13] and Tham et al. [14] proved that
N0 NPC patients with RLN alone have a similar risk of
distant metastasis to patients with N1 disease. The pro-
posal that patients with RLN should be classified with
N1 disease formed the basis of the revisions to the N0/
N1 classifications in the seventh edition of the AJCC
staging system. In this study, all patients underwent
magnetic resonance imaging (MRI) examinations and
received IMRT as their primary treatment. In patients
with negative cervical lymph node involvement, the pre-
sence of RLN metastasis was found to negatively affect
both DMFS, indicating it is still appropriate to classify
RLN metastasis as N1 disease, even in the era of
improved NPC treatment and diagnosis.
Local recurrence
IMRT is considered to be an advantageous radiation
treatment technique compared to conventional two-
dimensional radiation. IMRT can deliver high-dose irra-
diation to defined tumor targets, while minimizing the
dose delivered to the surrounding normal organs and
tissues, thereby improving the therapeutic ratio of radia-
tion therapy [7]. IMRT has improved the treatment
Figure 2 Five year overall survival, local relapse-free survival and distant metastasis-free survival for patients with N0 disease
according to the seventh edition of the American Joint Committee on Cancer (AJCC) nasopharyngeal carcinoma staging system.
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this study 5-year LRFS for all patients was 93.7%, similar
to the local control rates of 90%-97% achieved in other
studies using IMRT [8-11,19]. In N0 disease, we
achieved an excellent local control rate of 96.3%.
Distant metastasis
In NPC patients treated with two-dimensional conven-
tional radiotherapy, prognostic factors such as paraphar-
yngeal space extension, cranial nerve palsy and
intracranial extension are validated prognostic factors
for distant metastasis [5]. However, in our cohort of N0
patients treated with IMRT, no prognostic factor could
significantly determine DMFS, which may be due to the
excellent local control offered by IMRT, which reduces
the rate of metastasis and may weaken the significance
of potential prognostic factors.
Regional recurrence
Radiation oncologists have previously treated all neck
node levels in NPC comprehensively with definitive
intent radiotherapy or prophylactic irradiation [20]. Sev-
eral investigators confirmed that elective level II, III, and
VA irradiation is suitable for NPC without lymph node
metastasis [4,21]. Therefore, the volume of N0 disease
that requires irradiation can vary among different
doctors. As a result, only 43.6% N0 disease patients,
who had no cervical lymph nodes or RLN metastasis
based on MRI, received prophylactic irradiation to the
upper neck lymph drainage region in this study. Only
one failure was observed in a patient who developed
Level II lymph node recurrence after receiving prophy-
lactic irradiation of the retropharyngeal area and Level
II, III, IV, and V lymph node regions. It should be
emphasized that this patient developed a local recur-
rence, and so it is unclear whether the regions of lymph
node recurrence received efferent lymphatics from the
local recurrence
Using MRI, false negative diagnoses of metastases in the
neck regions are relatively rare, with an occurrence rate of
0.5% [21]. Furthermore, high-dose irradiation of the neck
area is associated with side effects, such as soft tissue fibro-
sis, which may adversely affect the patients’ quality of life
[22]. Our data confirmed that prophylactic irradiation
which excludes the Level IV and the supraclavicular region
does not increase the risk of regional recurrence in patients
classified with N0 disease according to the seventh edition
of the AJCC staging system using MRI again.
Survival of N0 disease according to AJCC T-classification
T1N0, T2N0 and T3N0 showed excellent survival rates
in this study. Tham et al. [11] reported excellent
Figure 3 Overall survival, local relapse-free survival and distant metastasis-free survival for different T-categories, according to the
seventh edition of the AJCC nasopharyngeal carcinoma staging system.
Table 3 Five-year survival rates for N0 nasopharyngeal carcinoma patients according to different T-classifications of
the seventh edition of AJCC staging system
Stage Death Local recurrence Distant metastasis
Event/N 5-year OS (%) Event/N 5-year LRFS (%) Event/N 5-year DMFS (%)
T1N0 1/60 97.8 0/60 100 2/60 96.6
T2N0 0/16 100 1/16 92.9 1/16 90.9
T3N0 1/16 93.8 0/16 100 0/16 100
T4N0 4/18 76.9 2/18 88.9 1/18 93.3
OS, overall survival; LRFS, local relapse-free survival; DMFS, distant metastasis-free survival
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ence in the LRFS rates of T1, T2 and T3 patients. We
focused on patients with N0 disease, in which the prog-
nostic factor of lymph nodes metastasis was excluded,
and found that the current TNM staging T-classification
is becoming less powerful for segregation of patients
into risk groups for local control and overall survival. In
practice, locoregional control in T1-T3 patients should
no longer be a major problem due to the improved out-
comes after IMRT treatment, accurate geographic cover-
age of tumors assisted by CT-guided radiation treatment
planning, increased diagnostic accuracy provided by
MRI and PET and the intensive use of chemotherapy.
Therefore, due to improved survival, it will become
increasingly important to pay attention to the long-term
complications of NPC treatment.
In this study, T4 patients had the poorest prognosis,
and T4 disease was the most challenging to treat. Ng et
al. also reported that advanced T4 disease remains diffi-
cult to treat [23]. Perhaps there are two main reasons.
Firstly, intracranial extension is a significant indepen-
dent predictor of LRFS in this study, as the adjacent
brainstem and spinal cord cannot tolerate radiation
doses at levels of 64 Gy in small volumes (1-10 mL)
[24]. When IMRT is administered proximal to critical
neurological structures, such as the brain stem, the very
steep dose gradient contributes to an inadequate tumor
dose and increases the risk of marginal failures. The risk
of marginal failures may be reduced by increasing the
precision of treatment using an adequate and very tight
dose coverage of target volumes. Image-guided radio-
therapy (IGRT) can potentially improve the accuracy of
radiotherapy treatment delivery, particularly within
high-dose gradients [25]. IMRT with IGRT could theo-
retically improve local control in T4N0 disease by redu-
cing the incidence of marginal failures, and this
hypothesis should be tested in the clinic. Secondly,
another possible explanation is that larger tumors of T4
disease need higher radiation doses for tumor control
due to the log-cell-kill principle of radiation treatment.
This need could be solved by increasing the physical
dose of radiation to an optimal level and/or by adminis-
tering accelerated fractionation to the tumor. Whole-
field simultaneous integrated-boost intensity-modulated
radiotherapy with a dose > 70 Gy achieved excellent
locoregional control, without an excess incidence of
severe [26]. However, it must be emphasized that this
was a retrospective study, and our conclusions need to
be confirmed by future prospective studies.
Conclusions
In summary, this study of NPC patients treated with
IMRT at a single institution offers valuable information
for the evaluation of prognosis in N0 disease in the
modern era. The seventh edition of the AJCC N-staging
system has improved the prognostic accuracy by
upgrading RLN metastasis to N1 disease. Prophylactic
irradiation excluding the Level IV and supraclavicular
region does not increase the risk of regional recurrence
in N0 disease. IMRT produces excellent survival rates in
T1-3 N0 disease, therefore, it will be increasingly impor-
tant to pay attention to the long-term complications of
treatment in T1-3 N0 NPC patients. However, T4N0
disease remains a challenge with poorer survival rates,
and additional improvements are required to achieve a
favorable prognosis for these patients.
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